Luzu
- Generic Name: luliconazole cream, 1%
- Brand Name: Luzu
Luzu (Luliconazole Cream, 1%) side effects drug center
- Related Drugs
- application site reactions such as skin irritation (contact dermatitis) or
- infection (cellulitis)
What Is Luzu?
Luzu (luliconazole) Cream, 1% is an azole antifungal agent used indicated to topically treat interdigital tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm of the body) caused by the organisms Trichophyton rubrum and Epidermophyton floccosum.
What Are Side Effects of Luzu?
Common side effects of Luzu Cream include:
Dosage for Luzu
Apply a thin layer of Luzu Cream, 1% to the affected area and approximately 1 inch of the immediate surrounding area(s) once daily for one (1) to two (2) weeks, depending on the organism being treated.
What Drugs, Substances, or Supplements Interact with Luzu?
Luzu may interact with other drugs. Tell your doctor all medications and supplements you use.
Luzu During Pregnancy and Breastfeeding
During pregnancy, Luzu Cream should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Luzu (luliconazole) Cream, 1% Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have severe burning, redness, swelling, or stinging after applying the medicine.
Common side effects may include mild skin irritation where the medicine was applied.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Luzu (Luliconazole Cream, 1%)
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In three Phase 3 clinical trials, 616 subjects were exposed to LUZU Cream, 1%: 305 with interdigital tinea pedis and 311 subjects with tinea cruris. Subjects with interdigital tinea pedis or tinea cruris applied LUZU Cream, 1% or vehicle cream once daily for 14 days or 7 days, respectively, to affected and adjacent areas. During clinical trials with LUZU Cream, 1%, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the LUZU and vehicle arms. Most adverse reactions were mild in severity.
A post-approval clinical trial was conducted in 75 subjects age 2 to <18 years old with tinea corporis. The adverse reactions in the LUZU Cream, 1% treated population were similar to the vehicle treated population.
Postmarketing Experience
The following adverse reactions have been identified during postmarketing use of luliconazole cream, 1%: contact dermatitis and cellulitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Read the entire FDA prescribing information for Luzu (Luliconazole Cream, 1%)
© Luzu Patient Information is supplied by Cerner Multum, Inc. and Luzu Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.